Placebo, 1-Isopropylnoradrenochrome-5-Monosemicarbazono and Pizotifen in Migraine Prophylaxis |
| |
| Authors: | P. Kangasniemi M.D. |
| |
| Affiliation: | Department of Neurology, University Central Hospital, Turku, Finland. |
| |
| Abstract: | SYNOPSIS
A new agent to be used in the prophylaxis of migraine has been developed. In addition to its antiserotonin effect it reduces vascular permeability. This preparation, 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol, was compared to pizotifen and to placebo by double-blind cross-over design. The doses were 15 mg respectively. 34 patients with severe and chronic migraine completed the study. The effects did not differ very much from each other. Pizotifen seemed to be more effective, but the semicarbozone derivative caused fewer side-effects. 14 patients reported no benefit from either preparation. |
| |
| Keywords: | |
|
|
